Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1987 1
1992 2
1997 1
2000 3
2002 1
2003 1
2004 3
2005 1
2007 2
2008 1
2009 3
2010 5
2011 6
2012 10
2013 4
2014 6
2015 4
2016 5
2017 1
2018 3
2019 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Oral hypoglycemic agents for gestational diabetes mellitus?
Maymone AC, Baillargeon JP, Ménard J, Ardilouze JL. Maymone AC, et al. Among authors: ardilouze jl. Expert Opin Drug Saf. 2011 Mar;10(2):227-38. doi: 10.1517/14740338.2011.521740. Epub 2011 Jan 6. Expert Opin Drug Saf. 2011. PMID: 21210750 Review.
CSII: Longer Catheter Usage Time, a Reasonable Goal.
Ardilouze JL, Ménard J, Gobeil F Jr, Gagnon-Auger M, Houde G, Pesant MH, Rabasa-Lhoret R, Baillargeon JP. Ardilouze JL, et al. J Diabetes Sci Technol. 2016 Jun 28;10(4):989-90. doi: 10.1177/1932296815622647. Print 2016 Jul. J Diabetes Sci Technol. 2016. PMID: 26682959 Free PMC article. No abstract available.
Update on adipose tissue blood flow regulation.
Sotornik R, Brassard P, Martin E, Yale P, Carpentier AC, Ardilouze JL. Sotornik R, et al. Among authors: ardilouze jl. Am J Physiol Endocrinol Metab. 2012 May 1;302(10):E1157-70. doi: 10.1152/ajpendo.00351.2011. Epub 2012 Feb 7. Am J Physiol Endocrinol Metab. 2012. PMID: 22318953 Free article.
Restoring ATBF: Dreaming the impossible dream?
Sotorník R, Gagnon-Auger M, Brassard P, Ardilouze JL. Sotorník R, et al. Among authors: ardilouze jl. Clin Hemorheol Microcirc. 2013 Jan 1;53(3):295-6. doi: 10.3233/CH-2012-1630. Clin Hemorheol Microcirc. 2013. PMID: 23075999 No abstract available.
65 results